Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inozyme Pharma Inc
(NQ:
INZY
)
5.540
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Inozyme Pharma Inc
< Previous
1
2
Next >
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
August 29, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 06, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
July 25, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
July 02, 2024
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
June 21, 2024
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
May 23, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
May 08, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 07, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
April 08, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
March 26, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
March 12, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
February 26, 2024
- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in Upcoming Investor Conferences
November 09, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 07, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
October 26, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
October 10, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
October 06, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
September 26, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
September 20, 2023
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 08, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.